Differences in Binding Affinity Between Integrase Inhibitors in HIV
An infectious disease specialist discusses the differences in binding affinity between dolutegravir and bictegravir and how it informs treatment selection.
EP: 1.The Role of the Primary Care Provider/Advanced Practice Provider in HIV Management
EP: 2.Evolving Treatment Practices and Guidelines for HIV
EP: 3.Key Clinical Considerations in HIV Treatment Decisions
EP: 4.HIV Treatment: Discussing Adverse Events with Patients
EP: 5.Importance of Starting HIV Treatment Early
EP: 6.Treatment Resistance in HIV
EP: 7.HIV Drug Resistance Testing Practices and Patient Education
EP: 8.Managing Suboptimal Adherence to HIV Medications
EP: 9.HIV Treatment Clinical Experiences
EP: 10.Addressing Suboptimal Treatment Response in HIV
EP: 11.Current HIV Treatment Regimens
EP: 12.Rapid Treatment Initiation in HIV
EP: 13.Switching Therapies for Patients with HIV and History of Resistance
EP: 14.Resources Available for Patients with HIV Drug Resistance
EP: 15.Factors that Inform Treatment Selection in HIV
EP: 16.Switching Therapies in HIV
EP: 17.Restarting Therapy in Patients with HIV
EP: 18.Treatment Guidelines and Regimens for Managing Patients with HIV
EP: 19.Differences in Binding Affinity Between Integrase Inhibitors in HIV
EP: 20.Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens
EP: 21.Recent Studies on HIV Treatments and Patient-Reported Outcomes
EP: 22.HIV: Treating Patients with Viral Mutations
Video content above is prompted by the following questions:
- Integrase inhibitors like dolutegravir and bictegravir bind to the active site of the integrase and as such suppress the HIV virus; they are integral to modern therapeutic algorithms.
- Can you explain the differences in binding affinity between dolutegravir and bictegravir and does this impact your treatment selection?
